Atrial Fibrillation (AF)
Conditions
Brief summary
Atrial fibrillation (AF) is a common heart rhythm disorder. While catheter ablation is an effective treatment, many patients still experience AF recurrence after the procedure. One major reason is that the mechanisms that maintain AF are not fully understood. Research suggests that the outer layer of the heart (epicardium) may play an important role in keeping AF going. However, current mapping techniques have limitations in detecting electrical signals from both the inner and outer heart layers. This study uses a different technique called unipolar voltage mapping, which may more accurately capture electrical signals from both heart layers. Specifically, we focus on a specific type of electrical signal called "QS potential" on unipolar mapping, which reflects breakthrough sites between the inner and outer heart layers. In this interventional study, participants with AF undergoing catheter ablation will receive personalized ablation guided by unipolar QS-potential mapping. We aim to: Explore the relationship between unipolar QS-potentials and AF maintenance and atrial remodeling Evaluate the effectiveness of QS-potential guided personalized AF ablation
Interventions
Participants in this arm undergo catheter ablation for atrial fibrillation guided by unipolar QS-potential mapping. Intracardiac unipolar voltage mapping is performed to identify QS-potentials, which reflect epicardial-endocardial breakthrough sites. Ablation is delivered to these identified target sites in addition to standard pulmonary vein isolation.
Participants in this arm undergo conventional pulmonary vein isolation for atrial fibrillation using standard bipolar voltage mapping. Ablation is performed to achieve electrical isolation of the pulmonary veins, without additional mapping-guided ablation beyond PVI.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age ≥ 18 years and ≤ 80 years * Documented diagnosis of atrial fibrillation (paroxysmal or persistent) * Planned to undergo catheter ablation for AF (including patients with recurrent AF after prior ablation) * Able and willing to provide written informed consent * Able to complete scheduled follow-up visits (3 months post-ablation)
Exclusion criteria
* Left ventricular ejection fraction \< 35% * Severe valvular heart disease (moderate to severe mitral stenosis or regurgitation) * History of intracardiac thrombus * Contraindication to anticoagulation * Active infection or sepsis * Pregnancy or breastfeeding * Life expectancy \< 12 months due to comorbid conditions * Participation in another interventional clinical trial within 30 days prior to enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from Atrial Fibrillation Recurrence at 3 Months Post Ablation | 3 months (from month 1 to month 6 post-ablation) | Freedom from any episode of atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) lasting ≥30 seconds, as detected by electrocardiogram (ECG) or 24-hour Holter monitoring, after a 3-month blanking period following the ablation procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total ablation time | Intraoperative (on the day of the ablation procedure) | Total duration of radiofrequency energy delivery during the ablation procedure, measured in minutes. This includes all ablation applications (both pulmonary vein isolation and additional lesion sets) from the first to the last energy application. |
Countries
China